InforSense Limited Used by Celera Corporation to Further Investigate Genetic Markers for Coronary Heart Disease

LONDON and CAMBRIDGE, MA--(Marketwire - April 27, 2009) - InforSense Ltd., the leading provider of next generation business and scientific intelligence solutions, today announced that Celera Corporation, a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries, is using InforSense to integrate internal molecular and public data sources to accelerate the successful identification of genetic markers, such as those Celera has reported for increased risk of Coronary Heart Disease (CHD).

The InforSense Translational Research Solution enables Celera to accelerate and automate many aspects of experimental data analysis and molecular annotation saving considerable time and effort. Celera and InforSense have developed a long-term relationship that covers the use of InforSense's Translational Research Solution to glean insight from available data and inform follow up studies for diagnostic markers of disease at Celera. These collaborative efforts complement and extend the pioneering informatics efforts of both companies independently.

InforSense has provided Celera with a configurable, scientist-friendly solution for translational research to support clinical data browsing, automated integration and analysis of enzyme linked immunoassay (ELISA), single nucleotide polymorphisms (SNPs) and other experimental proprietary and public data. By building bioinformatic queries and statistical analysis workflows, waiting times for scientists are significantly reduced and further investigation can focus on innovative developments saving valuable time and reducing costs. Celera used the knowledge gained from the identification of the gene variant in KIF6 that predicts CHD, to create and assemble key workflows, which streamline the overall process and provide for future acceleration of discovery efforts of this and other markers.

"A commercialization focus at Celera is developing advanced diagnostic biomarkers to detect, predict, characterize, monitor and select treatment for disease. We wanted to empower our scientists to be able to access and analyze a variety of orthologous clinical and experimental data to support biomarker discovery and InforSense has provided us with the means to do this," said John Sninsky, Vice President Research, Celera. "Fundamental contributions were made to disease understanding through InforSense solutions prioritizing literature queries and informing functional studies. Without these informatics tools, follow up studies of gene variants would be delayed."

"Celera is leading the way in developing new diagnostic biomarkers and we are delighted to be working with them in this vital field," said Jonathan Sheldon, Chief Science Officer, InforSense. "We are seeing increasing consistency and repetition in the market place for our productized approach to translational research informatics, which is increasingly being adopted in Pharmaceutical, Diagnostics, and Biotech companies as well as leading medical institutes. Not only does InforSense accelerate the biomarker discovery process, it slashes cost as well."

David Ross, Director of Computational Biology, Celera, will be presenting his findings on this project at the BioIT World Conference 2009. His talk is entitled "Assessment of the function and potential clinical relevance of gene variants from genome wide association studies using workflow-driven bioinformatics."

About InforSense Translational Research Solution

The InforSense Translational Research Solution provides a powerful and flexible framework to integrate and analyze clinical, patient specimen and experimental data for translational research. The solution builds on InforSense's expertise developing translational research analytics applications for the world's leading research institutes. It incorporates the power of the InforSense platform with expertise in micro-array analysis, cohort identification and clinical decision support and automated QC and analysis of Genome Wide Association Studies. InforSense text mining enables experimental results to form the basis of discovery in scientific literature and enables disease associations and other findings to be quickly established. InforSense Document Explorer is an ontology powered document viewer that is used to deliver the results of text mining to end users in an easy to use format. These tools enables translational analysis to be quickly implemented out of the box with minimum configuration, but enables best practice analytical workflows to be developed and modified by internal teams, providing the flexibility to manage this evolving research field. Features include:

--  Easy integration of data sets - All clinical, patient sample and
    experimental data can be integrated into a consistent informatics platform
    improving decision making by incorporating all available data
--  Simple web interface - Study designers and scientists can query and
    analyze the data through simple web interfaces produced by expert
    developers and statisticians, removing bottlenecks in accessing the data
--  Flexible platform - Workflows can be quickly developed and evolved
    enabling best practices to be flexibly optimized rather than needing to re-
    implement systems with each iteration
--  Advanced and scalable analytics - Proven scalability of the InforSense
    5.0 platform allows large data sets to analyzed using a wide variety of pre-
    integrated tools such as R and SAS providing a future proof environment.
    

About InforSense

InforSense delivers fast answers to complex questions in business, healthcare and life science. InforSense's next generation business and scientific intelligence solutions provide ROI in days, not months. Designed to handle today's complex business environments, where traditional BI products often fall short, the InforSense platform has the power and agility to integrate, analyze and visualize any data in any way. Around the world, leading pharmaceutical, biotechnology, consumer goods, healthcare, financial services, manufacturing and communications companies rely on InforSense. The company is privately held, with European headquarters in London, UK and North American headquarters in Cambridge, Massachusetts. For more information, visit www.inforsense.com and on Twitter at www.twitter.com/inforsense

InforSense and the InforSense logo are registered trademarks of InforSense Limited. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.